2250 GMT [Dow Jones]--Citi is slightly puzzled by the timing of pharmaceutical company CSL's CFO change. CSL says Joy Linton will step down as CFO on Oct. 7. She will be succeeded by Chief Strategy Officer Ken Lim and there will be a supporting transition period. "In our experience, major management change is unusual in the run-up to a big restructuring event like CSL's proposed spin-off of Seqirus, anticipated in 2H of FY 2026," analyst Laura Sutcliffe says. Citi assumes that Lim was heavily involved with the decision to spin off the vaccines business. It sees the personnel change as an opportunity for CSL to refresh goals and potentially higher-level strategy over time. Citi has a buy call and A$265.00/share price target on CSL, which ended Tuesday at A$198.20. (david.winning@wsj.com)
(END) Dow Jones Newswires
September 30, 2025 18:54 ET (22:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.